AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28322669 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month walking intervention
Number of subjects: 81
Study 26609786 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin administered through venous line
Number of subjects: 16
Study 26609786 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin administered through arterial line
Number of subjects: 16
Study 26609786 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous line administration of enoxaparin
Number of subjects: 16
Study 24921919 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment and surgery
Number of subjects: 375
Study 24921919 — intervention group
Group type: COMPARATOR
Intervention: Definitive chemoradiotherapy
Number of subjects: 375
Study 22181014 — intervention group
Group type: EXPERIMENTAL
Intervention: High caseworker support
Number of subjects: 1098
Study 22181014 — intervention group
Group type: EXPERIMENTAL
Intervention: High caseload size
Number of subjects: 1098
Study 22181014 — intervention group
Group type: EXPERIMENTAL
Intervention: High emphasis on employment
Number of subjects: 1098
Study 22181014 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic trajectories
Number of subjects: 1098
Study 19918972 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (4-g bolus dose)
Number of subjects: 9
Study 19918972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 17852632 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-down regimen (5.0 mg/kg per day starting dose and decreasing regimen)
Number of subjects: 61
Study 17852632 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen (2.5 mg/kg per day starting dose and increasing regimen)
Number of subjects: 61
Study 16159831 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 75
Study 16159831 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 75
Study 12121425 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone back extension exercise no. 5 (raising trunk, legs, and arms)
Number of subjects: 20
Study 12121425 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone back extension exercises (other than exercise no. 5)
Number of subjects: 20
Study 10633202 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly ferrous sulfate (60 mg elemental iron)
Number of subjects: 193
Study 10633202 — intervention group
Group type: COMPARATOR
Intervention: Daily ferrous sulfate (60 mg elemental iron)
Number of subjects: 193
Study 7759724 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioabsorbable hemostatic puncture closure device
Number of subjects: 435
Study 7759724 — intervention group
Group type: COMPARATOR
Intervention: Manual pressure control
Number of subjects: 435
Study 2275646 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverberant room with T = 0.54 s
Number of subjects: 3
Study 2275646 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverberant room with T = 1.55 s
Number of subjects: 3
Study 2275646 — intervention group
Group type: COMPARATOR
Intervention: Sound suite (quiet)
Number of subjects: 3
Study 2275646 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise condition
Number of subjects: 3
Study 2275646 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction of noise and room reverberation
Number of subjects: 3
Study 30476654 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin/rifampicin combination therapy
Number of subjects: 9
Study 30476654 — intervention group
Group type: COMPARATOR
Intervention: Colistin monotherapy
Number of subjects: 9
Study 30476654 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin/rifampicin combination therapy with 'partial synergy'
Number of subjects: 9
Study 30476654 — intervention group
Group type: COMPARATOR
Intervention: Colistin/rifampicin combination therapy with 'indifferent' results
Number of subjects: 9
Study 28412111 — intervention group
Group type: EXPERIMENTAL
Intervention: Apneic oxygen insufflation (AOI) at 3 L/min for 30 minutes during one-lung ventilation (OLV)
Number of subjects: 90
Study 28412111 — intervention group
Group type: COMPARATOR
Intervention: Non-AOI (control group)
Number of subjects: 90
Study 28412111 — intervention group
Group type: EXPERIMENTAL
Intervention: Apneic oxygen insufflation (AOI)
Number of subjects: 90
Study 25520389 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 6390
Study 25520389 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and/or NSAIDs
Number of subjects: 6390
Study 25520389 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 6390
Study 23840145 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant therapy (antox version 1.2-based)
Number of subjects: 7
Study 23840145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 23840145 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant therapy
Number of subjects: 7
Study 22929851 — intervention group
Group type: EXPERIMENTAL
Intervention: Septal quilting
Number of subjects: 85
Study 22929851 — intervention group
Group type: COMPARATOR
Intervention: BIPP packing
Number of subjects: 85
Study 20025374 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational interventions (BMI)
Number of subjects: 335
Study 20025374 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol expectancy challenge (AEC)
Number of subjects: 335
Study 17055622 — intervention group
Group type: EXPERIMENTAL
Intervention: Reformulated oral cholera vaccine
Number of subjects: 144
Study 17055622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 15326073 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/d
Number of subjects: 70
Study 15326073 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 70
Study 11883335 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy urease test
Number of subjects: 156
Study 11883335 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG ELISA
Number of subjects: 156
Study 9449446 — intervention group
Group type: EXPERIMENTAL
Intervention: Covering colostomy (n = 19)
Number of subjects: 38
Study 9449446 — intervention group
Group type: COMPARATOR
Intervention: No covering colostomy (n = 19)
Number of subjects: 38
Study 7677828 — intervention group
Group type: EXPERIMENTAL
Intervention: Active allergen avoidance treatment (n = 17)
Number of subjects: 35
Study 7677828 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 18)
Number of subjects: 35
Study 2904753 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (2 to 8 mg)
Number of subjects: 40
Study 2904753 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (100 mg)
Number of subjects: 40
Study 30918221 — intervention group
Group type: COMPARATOR
Intervention: Serum TG level <100 mg/dL
Number of subjects: 652
Study 30918221 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum TG level ≥100 mg/dL
Number of subjects: 652
Study 27778264 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment plus Chinese herbal medicines (CHMs) for benefiting qi and activating blood circulation
Number of subjects: 702
Study 27778264 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 702
Study 26219416 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning meal (0800 hours)
Number of subjects: 20
Study 26219416 — intervention group
Group type: COMPARATOR
Intervention: Evening meal (2000 hours)
Number of subjects: 20
Study 23288773 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-eccentric exercise (CEE) 3 times per week
Number of subjects: 42
Study 23288773 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-eccentric exercise (CEE) 5 times per week
Number of subjects: 42
Study 23288773 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CEE)
Number of subjects: 42
Study 22126827 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD risk message
Number of subjects: 781
Study 22126827 — intervention group
Group type: EXPERIMENTAL
Intervention: Planning tool
Number of subjects: 781
Study 22126827 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD risk message plus planning
Number of subjects: 781
Study 22126827 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 781
Study 18434639 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 g/day mycophenolate mofetil (MMF) plus 20 mg/day prednisone
Number of subjects: 80
Study 18434639 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus 20 mg/day prednisone
Number of subjects: 80
Study 17057572 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (group L)
Number of subjects: 88
Study 17057572 — intervention group
Group type: COMPARATOR
Intervention: Mini-laparotomy cholecystectomy (group M)
Number of subjects: 88
Study 13677549 — intervention group
Group type: EXPERIMENTAL
Intervention: Ortho Tri-Cyclen LO (norgestimate 180/215/250 microg/EE 25 microg)
Number of subjects: 864
Study 13677549 — intervention group
Group type: COMPARATOR
Intervention: Loestrin Fe 1/20 (norethindrone acetate 1 mg/EE 20 microg)
Number of subjects: 864
Study 13677549 — intervention group
Group type: EXPERIMENTAL
Intervention: Ortho Tri-Cyclen LO
Number of subjects: 864
Study 13677549 — intervention group
Group type: COMPARATOR
Intervention: Loestrin Fe 1/20
Number of subjects: 864
Study 13677549 — intervention group
Group type: EXPERIMENTAL
Intervention: Ortho Tri-Cyclen to Ortho Tri-Cyclen LO switchovers
Number of subjects: 864
Study 10766680 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive management strategy
Number of subjects: 413
Study 8874906 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine (5 micrograms . kg‐1) administered 1.5 hr before surgery, and at 12 hr and 24 hr after initial dose
Number of subjects: 39
Study 8874906 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine
Number of subjects: 39
Study 8874906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 1411952 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour treatment (cefoxitin or cefotetan)
Number of subjects: 515
Study 1411952 — intervention group
Group type: COMPARATOR
Intervention: 5-day treatment
Number of subjects: 515
Study 1411952 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour treatment (cefoxitin or cefotetan) in high-risk group (colon wounds)
Number of subjects: 515
Study 1411952 — intervention group
Group type: COMPARATOR
Intervention: 5-day treatment in high-risk group (colon wounds)
Number of subjects: 515
Study 1411952 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour treatment (cefoxitin or cefotetan) in high-risk group (ATI > 25)
Number of subjects: 515
Study 1411952 — intervention group
Group type: COMPARATOR
Intervention: 5-day treatment in high-risk group (ATI > 25)
Number of subjects: 515
Study 2932705 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg (group B)
Number of subjects: 81
Study 2932705 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg (group C)
Number of subjects: 81
Study 2932705 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group A)
Number of subjects: 81
Study 2932705 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 81
Study 28906317 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG3350 with electrolytes (PEG3350 + E)
Number of subjects: 97
Study 28906317 — intervention group
Group type: COMPARATOR
Intervention: PEG4000 without electrolytes (PEG4000)
Number of subjects: 97
Study 28716141 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent activation therapy for people with MCI or mild to moderate dementia and a brief telephone intervention for informal caregivers.
Number of subjects: 346
Study 28716141 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (waitlist control group).
Number of subjects: 346
Study 28716141 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent activation therapy and caregiver counselling.
Number of subjects: 346
Study 26329163 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years Parents and Babies Program
Number of subjects: 128
Study 26329163 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 128
Study 23945510 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 1 μg/kg
Number of subjects: 60
Study 23945510 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexmedetomidine 1 μg/kg
Number of subjects: 60
Study 23945510 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (Control)
Number of subjects: 60
Study 22042184 — intervention group
Group type: EXPERIMENTAL
Intervention: Horse riding simulator (RS)
Number of subjects: 40
Study 22042184 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy (CT)
Number of subjects: 40
Study 18427233 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric contraction of the masseter muscles
Number of subjects: 0
Study 18427233 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline measurements
Number of subjects: 0
Study 18427233 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated job interview (inducing cardiovascular responses)
Number of subjects: 0
Study 18427233 — intervention group
Group type: COMPARATOR
Intervention: Control group (pain-free individuals)
Number of subjects: 0
Study 16950290 — intervention group
Group type: EXPERIMENTAL
Intervention: Venom Immunotherapy (VIT)
Number of subjects: 193
Study 16950290 — intervention group
Group type: COMPARATOR
Intervention: EpiPen
Number of subjects: 193
Study 15367074 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling (up to 5 sessions)
Number of subjects: 3522
Study 15367074 — intervention group
Group type: COMPARATOR
Intervention: Self-help booklets only
Number of subjects: 3522
Study 11305625 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated food diary record (ED) method
Number of subjects: 72
Study 11305625 — intervention group
Group type: COMPARATOR
Intervention: Weighed intake record method (WI)
Number of subjects: 72
Study 11305625 — intervention group
Group type: COMPARATOR
Intervention: Doubly labelled water (DLW) method
Number of subjects: 72
Study 9048792 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine (1 mg intravenously)
Number of subjects: 40
Study 9048792 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin (40 U intravenously)
Number of subjects: 40
Study 8328080 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (800 micrograms twice daily)
Number of subjects: 40
Study 8328080 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (750 micrograms twice daily)
Number of subjects: 40
Study 3551508 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid treatment (10 ml of an antacid suspension, buffering capacity 85 mmol/10 ml, administered 1 and 3 hours after each meal and at bedtime)
Number of subjects: 67
Study 3551508 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (400 mg b.i.d.)
Number of subjects: 67
Study 3551508 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid treatment
Number of subjects: 67
Study 3551508 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine treatment
Number of subjects: 67
Study 29337126 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid Plate Fixation (RPF)
Number of subjects: 236
Study 29337126 — intervention group
Group type: COMPARATOR
Intervention: Wire Cerclage (WC)
Number of subjects: 236
Study 27178435 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitopertin 3 mg
Number of subjects: 46
Study 27178435 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitopertin 10 mg
Number of subjects: 46
Study 27178435 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitopertin 30 mg
Number of subjects: 46
Study 27178435 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitopertin 60 mg
Number of subjects: 46
Study 27178435 — intervention group
Group type: COMPARATOR
Intervention: RG7118 15 mg
Number of subjects: 46
Study 27178435 — intervention group
Group type: COMPARATOR
Intervention: RG7118 30 mg
Number of subjects: 46
Study 27178435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 24768084 — intervention group
Group type: EXPERIMENTAL
Intervention: Masai Barefoot Technology shoes
Number of subjects: 17
Study 24768084 — intervention group
Group type: COMPARATOR
Intervention: Control shoes
Number of subjects: 17
Study 22565898 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliac crest flap
Number of subjects: 0
Study 22565898 — intervention group
Group type: COMPARATOR
Intervention: Fibular flap
Number of subjects: 0
Study 20980657 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified complementary food (FC)
Number of subjects: 246
Study 20980657 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified flour (FF)
Number of subjects: 246
Study 20980657 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 246
Study 18773822 — intervention group
Group type: EXPERIMENTAL
Intervention: New One‐Stitch technique
Number of subjects: 445
Study 18773822 — intervention group
Group type: COMPARATOR
Intervention: Lich‐Gregoir technique
Number of subjects: 445
Study 15836685 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercapnia (end‐tidal CO(2) = 45 mmHg) with thiopental and isoflurane (TI)
Number of subjects: 24
Study 15836685 — intervention group
Group type: COMPARATOR
Intervention: Normocapnia (end‐tidal CO(2) = 35 mmHg) with thiopental and isoflurane (TI)
Number of subjects: 24
Study 15836685 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercapnia (end‐tidal CO(2) = 45 mmHg) with propofol (P)
Number of subjects: 24
Study 15836685 — intervention group
Group type: COMPARATOR
Intervention: Normocapnia (end‐tidal CO(2) = 35 mmHg) with propofol (P)
Number of subjects: 24
Study 11703572 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) plus ribavirin for 48 weeks
Number of subjects: 912
Study 11703572 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) plus ribavirin for 24 weeks
Number of subjects: 912
Study 11703572 — intervention group
Group type: COMPARATOR
Intervention: Interferon (IFN) alone for 24 weeks
Number of subjects: 912
Study 9143608 — intervention group
Group type: EXPERIMENTAL
Intervention: D0870 (50 mg initial dose followed by 10 mg for 4 days)
Number of subjects: 35
Study 9143608 — intervention group
Group type: EXPERIMENTAL
Intervention: D0870 (100 mg initial dose followed by 25 mg for 4 days)
Number of subjects: 35
Study 9143608 — intervention group
Group type: EXPERIMENTAL
Intervention: D0870 (100 mg initial dose followed by 10 mg for 5 days)
Number of subjects: 35
Study 9143608 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 35
Study 8196572 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine (450 mg per day)
Number of subjects: 95
Study 8196572 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine
Number of subjects: 95
Study 8196572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 3310504 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% dextrose solution (dextrose group)
Number of subjects: 48
Study 3310504 — intervention group
Group type: EXPERIMENTAL
Intervention: Hartmann's solution (Hartmann group)
Number of subjects: 48
Study 3310504 — intervention group
Group type: COMPARATOR
Intervention: No intravenous infusion (control group)
Number of subjects: 48
Study 29382398 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmanned Aerial Vehicle (UAV) technology
Number of subjects: 21
Study 29382398 — intervention group
Group type: COMPARATOR
Intervention: Standard Practice (SP)
Number of subjects: 21
Study 29382398 — intervention group
Group type: EXPERIMENTAL
Intervention: UAV
Number of subjects: 21
Study 29382398 — intervention group
Group type: COMPARATOR
Intervention: SP
Number of subjects: 21
Study 29382398 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 21
Study 26810770 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 237
Study 26810770 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecure-dismissing attachment style
Number of subjects: 237
Study 26810770 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient characteristics (Black American, younger, never married, poorer)
Number of subjects: 237
Study 23490463 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic Gait Training
Number of subjects: 60
Study 23490463 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill Training
Number of subjects: 60
Study 23490463 — intervention group
Group type: COMPARATOR
Intervention: Physical Therapy
Number of subjects: 60
Study 21177084 — intervention group
Group type: EXPERIMENTAL
Intervention: bakumondoto
Number of subjects: 24
Study 21177084 — intervention group
Group type: COMPARATOR
Intervention: Control (no bakumondoto)
Number of subjects: 24
Study 19564317 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 355
Study 19564317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 355
Study 19564317 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin and Placebo
Number of subjects: 355
Study 19564317 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe brain injury
Number of subjects: 355
Study 19564317 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioeconomic factors
Number of subjects: 355
Study 16389065 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized (broad) cognitive behavioral therapy
Number of subjects: 50
Study 16389065 — intervention group
Group type: COMPARATOR
Intervention: Manual‐based (focused) cognitive behavioral therapy
Number of subjects: 50
Study 15172366 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric implementations of model observers (channelized hotelling observer and non-prewhitening matched filter)
Number of subjects: 0
Study 15172366 — intervention group
Group type: COMPARATOR
Intervention: Human observer detection performance
Number of subjects: 0
Study 11251036 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone infusion (100 mg followed by continuous infusion of 0.18 mg/kg per h)
Number of subjects: 24
Study 11251036 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study 9235736 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 2.0 IU/m2, Norditropin
Number of subjects: 29
Study 9235736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 7516831 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum PSA and DRE as first approach, followed by TRUS if abnormal
Number of subjects: 7350